Not Disclosed (Platform-derived)
Cancer / Autoimmune Diseases
Key Facts
About CDR-Life
CDR-Life is a private, clinical-stage biotech leveraging its M-gager® T cell engager platform to create targeted therapies for solid tumors and autoimmune conditions. Founded by experienced drug developers, the company has generated six development candidates, with two already in clinical testing. Backed by a $76M Series A and strategic partnerships, CDR-Life is positioned to advance transformative treatments for hard-to-treat diseases.
View full company profileAbout CDR-Life
CDR-Life is a private, clinical-stage biotech leveraging its M-gager® T cell engager platform to create targeted therapies for solid tumors and autoimmune conditions. Founded by experienced drug developers, the company has generated six development candidates, with two already in clinical testing. Backed by a $76M Series A and strategic partnerships, CDR-Life is positioned to advance transformative treatments for hard-to-treat diseases.
View full company profileAbout CDR-Life
CDR-Life is a private, clinical-stage biotech leveraging its M-gager® T cell engager platform to create targeted therapies for solid tumors and autoimmune conditions. Founded by experienced drug developers, the company has generated six development candidates, with two already in clinical testing. Backed by a $76M Series A and strategic partnerships, CDR-Life is positioned to advance transformative treatments for hard-to-treat diseases.
View full company profileAbout CDR-Life
CDR-Life is a private, clinical-stage biotech leveraging its M-gager® T cell engager platform to create targeted therapies for solid tumors and autoimmune conditions. Founded by experienced drug developers, the company has generated six development candidates, with two already in clinical testing. Backed by a $76M Series A and strategic partnerships, CDR-Life is positioned to advance transformative treatments for hard-to-treat diseases.
View full company profileAbout CDR-Life
CDR-Life is a private, clinical-stage biotech leveraging its M-gager® T cell engager platform to create targeted therapies for solid tumors and autoimmune conditions. Founded by experienced drug developers, the company has generated six development candidates, with two already in clinical testing. Backed by a $76M Series A and strategic partnerships, CDR-Life is positioned to advance transformative treatments for hard-to-treat diseases.
View full company profileAbout CDR-Life
CDR-Life is a private, clinical-stage biotech leveraging its M-gager® T cell engager platform to create targeted therapies for solid tumors and autoimmune conditions. Founded by experienced drug developers, the company has generated six development candidates, with two already in clinical testing. Backed by a $76M Series A and strategic partnerships, CDR-Life is positioned to advance transformative treatments for hard-to-treat diseases.
View full company profile